Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4640091 | 0.89 | CSNK2A2 (0.33) | CSNK2A2CSNK2BCSNK2A1ARPDE2A | |
| SCHEMBL2085441 | 0.80 | CSNK2A2 (0.37) | CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL2085120 | 0.79 | CSNK2A2 (0.42) | CSNK2A2CSNK2BCSNK2A1ALDH1A1 | |
| SCHEMBL2084414 | 0.79 | CRHR1 (0.40) | CSNK2A2CSNK2BCSNK2A1ALDH1A1BRAF | |
| SCHEMBL2085651 | 0.77 | DAO (0.38) | CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL3215105 | 0.77 | DAO (0.44) | CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1 | |
| SCHEMBL2084897 | 0.76 | L3MBTL1 (0.36) | CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1 | |
| SCHEMBL2085548 | 0.73 | PLAT (0.34) | CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1 | |
| SCHEMBL2082774 | 0.73 | KDM4E (0.38) | KDM4EALDH1A1 | |
| SCHEMBL2085547 | 0.73 | PLAT (0.34) | CSNK2A2CSNK2BCSNK2A1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163935-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090312383-A1 | Fused Heterocyclic Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312383-A1 | Fused Heterocyclic Compounds | NPY4R, CRHR1, CNR1 | CSNK2A2 731/4885CSNK2B 596/4885CSNK2A1 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.